ConductScience.org, home

Trial · NCT03260205

Results by group224

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change From Baseline in Clinician-Administered Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version Total Score at Week 6Placebo-9.1Standard Error 2.36Score on a scale
Change From Baseline in Clinician-Administered Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version Total Score at Week 6Pooled SPD489 Doses (10, 20, and 30 mg)-14.2Standard Error 1.57Score on a scale
Clinical Global Impressions Global Improvement (CGI-I) at Week 6Placebo3.4Standard Error 0.18Score on a scale
Clinical Global Impressions Global Improvement (CGI-I) at Week 6Pooled SPD489 Doses (10, 20, and 30 mg)2.8Standard Error 0.13Score on a scale
Dose Response Relationship for Change From Baseline in ADHD-RS-IV Preschool Version Total Score in Preschool Children at Week 6Placebo-9.1Standard Error 2.36Score on a scale
Dose Response Relationship for Change From Baseline in ADHD-RS-IV Preschool Version Total Score in Preschool Children at Week 6SPD489 30 mg-15.3Standard Error 2.62Score on a scale
Dose Response Relationship for Change From Baseline in ADHD-RS-IV Preschool Version Total Score in Preschool Children at Week 6SPD489 20 mg-17.0Standard Error 2.90Score on a scale
Dose Response Relationship for Change From Baseline in ADHD-RS-IV Preschool Version Total Score in Preschool Children at Week 6SPD489 10 mg-10.8Standard Error 2.63Score on a scale
Dose Response Relationship for Change From Baseline in ADHD-RS-IV Preschool Version Total Score in Preschool Children at Week 6SPD489 5 mg-13.5Standard Error 2.53Score on a scale
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Placebo19Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)SPD489 5 mg13Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)SPD489 10 mg15Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)SPD489 20 mg18Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)SPD489 30 mg22Participants
Number of Participants With Potentially Clinically Significant Changes in Vital SignsPlaceboPulse: >=130 beats per minute (bpm), Week 60Participants
Number of Participants With Potentially Clinically Significant Changes in Vital SignsSPD489 5 mgPulse: >=130 beats per minute (bpm), Week 60Participants
Number of Participants With Potentially Clinically Significant Changes in Vital SignsSPD489 10 mgPulse: >=130 beats per minute (bpm), Week 60Participants
Number of Participants With Potentially Clinically Significant Changes in Vital SignsSPD489 20 mgPulse: >=130 beats per minute (bpm), Week 60Participants
Number of Participants With Potentially Clinically Significant Changes in Vital SignsSPD489 30 mgPulse: >=130 beats per minute (bpm), Week 60Participants
Number of Participants With Potentially Clinically Significant Changes in Vital SignsPlaceboPulse: <=55 bpm, Week 60Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03260205/results